Bayer to Spend $700 Million Making New Hemophilia Drugs in Germany, Not Berkeley

The Germany-based drug maker makes the blood-clotting hemophilia A drug Kogenate in Berkeley and recommitted to that facility in 2011 with a four-year contract for its unionized workforce. But the company said Tuesday that two experimental drugs will add to its pipeline and it needs to expand German facilities in Leverkusen and Wuppertal by 2020.s